Introduction
============

Vascular lesions/angioectasia are the most common source of small bowel (SB) bleeding [@JR1739-1] . Although their pathogenesis is poorly understood, it is felt to relate to age and strain on the intestinal wall [@JR1739-2] with chronic hypoperfusion of the bowel hypothesized to contribute [@JR1739-3] . Mid gut bleeding is often precipitated by impaired clotting. This can be through medical anticoagulation and/or antiplatelet therapy or due to complicated and poorly understood sequalae of comorbidities, which often accumulate with age. For example, aortic valve stenosis (AoVS) is speculated to result in turbulent blood flow, which proteolyses von Willebrand (VWF) factor, and the resultant deficiency can propagate gastrointestinal bleeding [@JR1739-4] . Chronic kidney disease (CKD) results in increased bleeding through impaired platelet function and platelet vessel wall interactions [@JR1739-5] [@BR1739-6] . As such, presentations with SB bleeding secondary to angioectasia could be felt to be a marker of frailty with age and comorbidity leading to initial formation and possible bleeding.

The aim of this study was to review survival in patients diagnosed with bleeding SB angioectasia, with the hypothesis that many will die due to organ failure and comorbidity rather than gastointestinal bleeding.

Patients and methods
====================

A prospectively populated database of small bowel capsule endoscopy (SBCE) procedures was retrospectively reviewed for cases were angioectasia were isolated as the cause of SB bleeding. One hundred twenty-five SBCEs fulfilled the criteria (i. e. angioectasia as the cause of SB bleeding and performed prior to June 2014, ensuring availability of 5-year survival data). They were retrospectively analysed with further information on the clinical course, management, number of angioectasia seen along with mortality and comorbidity gathered through hospital records.

Data from an age- and gender-matched group with "normal" SBCE procedures was also extracted. These patients were also all investigated for iron deficiency anemia or occult gastrointestinal bleeding but without any abnormality of the small bowel identified. Microsoft Excel (Microsoft Corporation, Washington, United States) was used to collate, analyse and graph the results.

Results
=======

Demographics and comorbidities
------------------------------

At the time of SBCE, patients with isolated angioectasia had a median age of 72.7 (IQR 63.2--77.7) years, 69 female: 56 male. Those with a "normal" SBCE also had a median age of 72.7 (IQR 62.9--78.1) years, again 69 female: 56 male.

Comorbidities were common in both groups and are shown in [Table 1](#TB1739-1){ref-type="table"} . Cardiac, vascular, and renal disease was more common in those found to have angioectasia.

###### Comorbidities.

  Comorbidity                            Angioectasia   Normal CE
  -------------------------------------- -------------- -----------
  Cardiac/vascular                                      
  Ischemic heart disease                 28 (22.4)      25 (20)
  LVSD/CCF                               24 (19.2)      17 (13.6)
  Cerebrovascular disease                19 (15.2)      15 (12)
  Aortic valve disease ± AVR             18 (14.4)      10 (8)
  Atrial fibrillation                    14 (11.2)      21 (16.8)
  AAA                                    11 (8.8)        1 (0.8)
  Peripheral vascular disease            11 (8.8)        4 (3.2)
  Mitral valve disease                    3 (2.4)        8 (6.4)
  Cardiomyopathy                          2 (1.6)        1 (0.8)
  Mesenteric ischemia                     1 (0.8)        0
  Diabetes                               30 (24)        23 (18.4)
  Dementia                                              
  Vascular                                3 (2.4)        2 (1.6)
  Alzheimer's                             2 (1.6)        3 (2.4)
  Mixed                                   1 (0.8)        2 (1.6)
  Liver cirrhosis                         9 (7.2)        5 (4.0)
  Viral hepatitis                         0              2 (1.6)
  Crohn\'s disease                        4 (3.2)        0
  Pancreatitis                            0              2 (1.6)
  Renal                                                 
  Chronic kidney disease                 18 (14.4)       9 (7.2)
  End stage renal failure/dialysis        4 (3.2)        0
  Respiratory                                           
  COPD                                   18 (14.4)      15 (12)
  Asthma                                  4 (3.2)        2 (1.6)
  Bronchiectasis                          0              1 (0.8)
  Pulmonary fibrosis                      0              2 (1.6)
  Hereditary hemorrhagic telangectasia    3 (2.4)        0
  Hematological                                         
  Platelet release defect                 2 (1.6)        0
  ITP                                     1 (0.8)        0
  Myelodysplasia                          1 (0.8)        1 (0.8)
  Factor V Leiden                         1 (0.8)        0
  VWF                                     1 (0.8)        1 (0.8)
  MGUS                                    0              2 (1.6)
  Borderline factor XI                    0              1 (0.8)
  Vasculitis                              0              1 (0.8)
  Malignancy                                            
  Breast                                  0              4 (3.2)
  Bladder                                 0              1 (0.8)
  Vulval                                  0              1 (0.8)
  Rectal                                  0              1 (0.8)
  Prostate                                1 (0.8)        2 (1.6)
  Melanoma                                0              3 (2.4)
  Parkinson's disease                     0              1 (0.8)
  Hereditary spastic paraplegia           0              1 (0.8)

CE, capsule endoscopy; LVSD, left ventricular systolic dysfunction; CCF, congestive cardiac failure; AVR, aortic valve replacement; AAA, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; ITP, immune thrombocytopenic purpura; VWF, von Willebrand factor; MGUS, monoclonal gammopathy of undetermined significance

Five-year survival
------------------

Of the 125 patients with angioectasia on their SBCE, 64 had died by the end of the study period (June 2019) with 45 of these deaths within 5 years of their index SBCE ( [Fig. 1](#FI1739-1){ref-type="fig"} ). Overall 5-year survival was 64.0 % (80/125). Median age at death was 78 years (IQR 73--83) in those that died by the end of follow-up. Five-year survival was 70.4 % (88/125 in those with "normal" SBCE. Median age at death in those who had died by the end of the study was 81.0 years.

![ Five-year survival post diagnosis with angioectasia vs those with "normal" SBCE.](10-1055-a-1180-8319-i1739ei1){#FI1739-1}

Impact of age and comorbidities
-------------------------------

Only 17.6 % of patients (22/125) with angioectasia had no major comorbidities and they were younger with a median age of 69.3 (IQR 61.0--75.0) years. Eight of 22 had died by the end of follow-up (June 2019) with a median age of 78 years (IQR 75.5--78.25). The rate of 5-year survival in those with no major comorbidities was 81.1 % (18/22), as shown in [Fig. 2](#FI1739-2){ref-type="fig"} .

![ Five-year survival in those with no major comorbidities compared to those \> 65 years of age with at least one major comorbidity following diagnosis of angioectasia .](10-1055-a-1180-8319-i1739ei2){#FI1739-2}

Eighty-nine were over age 65 years with angioectasia, 12 had incomplete notes due to being out of area, and a further 11 had no major comorbidities (including those with uncomplicated Type 2 diabetes or hypertension only). This left 66 for analysis who were aged over 65 (mean age 76.4 years) with at least one major comorbidity. 28.8 % (19/66) were alive at end of study period (June 2019) with a 5-year survival of 45.5 % (30/66) ( [Fig. 2](#FI1739-2){ref-type="fig"} ).

In those with normal SBCE procedures with one or more major comorbidity and age \> 65, 5-year survival was 57.4 % (39/68).

Patients with renal, cardiac or vascular comorbidity
----------------------------------------------------

Those with angioectasia and renal disease (CKD) had a 5-year survival of 61.9 % (11/19).

Fifty-six percent (70/125) of those with angioectasia causing their SB blood loss had at least one major cardiac or vascular comorbidity (ischemic heart disease, congestive cardiac failure, cerebrovascular accident, aortic or mitral disease, atrial fibrillation, abdominal aortic aneurysm, peripheral vascular disease, cardiomyopathy, mesenteric ischemia, intracerebral bleed). Those with cardiac/vascular disease had a 5-year survival of 52.9 % (37/70). They were slightly older at the time of SBCE with a median age of 75.5 (interquartile range 68.8--81.8) years. Those with cardiac/vascular disease taking antiplatelets/anticoagulants had a 5-year survival of 51.4 %, compared to 53.1 % in those who were not (one excluded from analysis for unclear documentation).

Of those without angioectasia, 50.4 % (63/125) had cardiac or vascular comorbidity, and their 5-year survival rate was higher at 63.5 %.

Causes of death
---------------

None of the deaths in those with SB bleeding secondary to angioectasia were documented as being directly attributable to gastrointestinal bleeding, although a significant number were from out of area and had incomplete documentation available following their death ( [Table 2](#TB1739-2){ref-type="table"} ).

###### List of causes of death.

  Pathology                                              Deaths in those with angioectasia (%)   Deaths in those without angioectasia (%)
  ------------------------------------------------------ --------------------------------------- ------------------------------------------
  Pneumonia/chest sepsis                                  7 (5.6)                                 6 (4.8)
  MI                                                      5 (4)                                   5 (4)
  Liver failure (NAFLD)                                   2 (1.6)                                 0
  COPD/bronchiectasis                                     2 (1.6)                                 1 (0.8)
  Cancer                                                  3 (2.4)                                11 (8.8)
  Bladder                                                 1 (0.8)                                 0
  NSCLC                                                   1 (0.8)                                 3 (2.4)
  SCLC                                                    0                                       2 (1.6)
  HCC                                                     0                                       1 (0.8)
  Breast                                                  0                                       1 (0.8)
  Gastric                                                 0                                       1 (0.8)
  Prostate                                                1 (0.8)                                 2 (1.6)
  Colon                                                   0                                       1 (0.8)
  Following ascitic drain                                 0                                       1 (0.8)
  Surgical complication                                   4 (3.2)                                 0
  Renal                                                   1 (0.8)                                 0
  Crohn\'s resection with dehiscence of SB anastomosis    1 (0.8)                                 0
  Adrenalectomy for Pheochromocytoma                      1 (0.8)                                 0
  Kidney/pancreas transplant                              1 (0.8)                                 0
  Ruptured AAA                                            2 (1.6)                                 0
  CCF secondary to AS                                     2 (1.6)                                 1 (0.8)
  CVA                                                     2 (1.6)                                 2 (1.6)
  CCF                                                     2 (1.6)                                 4 (3.2)
  Renal failure                                           2 (1.6)                                 1 (0.8)
  Intracranial hemorrhage                                 1 (0.8)                                 2 (1.6)
  PE                                                      1 (0.8)                                 0
  Biliary sepsis secondary to cholangiocarcinoma          1 (0.8)                                 0
  Ischemic colitis                                        1 (0.8)                                 1 (0.8)
  Rectal variceal bleed                                   0                                       1 (0.8)
  Upper gastrointestinal bleed (gastric ulcer)            0                                       1 (0.8)
  Unclear/unrecorded (many out of area)                  27 (21.6)                               14 (11.2)
  Alive                                                  61 (48.8)                               74 (59.2)

MI, myocardial infarction; NAFLD, non-alcoholic fatty liver disease; COPD, chronic obstructive pulmonary disease; NSCLC, non small cell lung carcinoma; HCC, hepatocellular carcinoma; SB, small bowel; AAA, abdominal aortic aneurysm; CCF, congestive cardiac failure; AS, aortic stenosis; CVA, cerebrovascular accident; PE, pulmonary embolism.

Two deaths in the group with no SB abnormalities on CE were due to uncontrolled gastrointestinal bleeding, one case from rectal varices and one from a gastric ulcer. Both of these deaths occurred within a month of their normal SBCE investigation.

Number and extent of angioectasia
---------------------------------

A clear description of the extent of small bowel angioectatic disease was present in 71 of the cases. Of them, 41/71 (57.7 %) had one or two angioectasias. The 5-year survival in this group was 70.7 % (29/41). This group had a median age of 70.0 (IQR 61.4--76.1) years, with 28 (68.3 %) suffering major cardiac, vascular or renal comorbidity. Sixteen (39.0 %) were noted to be taking antiplatelets and/or anticoagulants. Thirty of 71 (42.3 %) of them had three or more angioectasias. This group was older with a median age of 76.2 years (IQR 69.3--80.4), with 19 (63.3 %) suffering major cardiac, vascular or renal comorbidity. Ten (33.3 %) were noted to be taking antiplatelets and/or anticoagulants. Their 5-year survival was 66.7 % (20/30).

Those with documentation giving an unclear description of the number of lesions (n = 54) were often older and largely from out of area. These patients had a median age of 71.8 and a 5-year survival rate of 57.7 % (31/54).

Endoscopic treatments given
---------------------------

Of the 125 patients with angioectasia isolated on their SBCE, 37 subsequently had endoscopic treatment with argon plasma coagulation (APC) planned (4 procedures later cancelled or failed): double balloon enteroscopy (DBE) (n = 22); push enteroscopy (PE) (n = 5); upper gastrointestinal endoscopy (n = 9) and colonoscopy (n = 1). These patients had a median age of 74.1 years. Those who underwent endoscopic therapy had a 5-year survival rate of 62.2 % (23/37).

Discussion
==========

The overall 5-year survival in those diagnosed with angioectasia on SBCE was 64.0 %. This is comparable to the 5-year mortality rate seen when SB adenocarcinoma (all SEER stages combined) is diagnosed (68 %) and worse than when the cancer is localised (85 % survival at 5 years) [@OR1739-7] . A similar study looking at all causes of occult SB bleeding had a 74.7 % 5-year survival rate compared to 89.3 % age matched cohort survival in Japan [@JR1739-8] . This would suggest that a diagnosis of SB angioectasia is both significant and associated with worse outcomes than serious alternative pathologies seen.

Those with a "normal" SB on SBCE (age and gender matched) were used as a comparison and had a 5-year survival rate of 70.4 % ( [Table 3](#TB1739-3){ref-type="table"} ). This is better than those with angioectasia but poorer than might have been expected. At ages 65 to 69 a man in the city of Edinburgh has a life expectancy of 18.0 years, and woman 20.5 years [@OR1739-9] . This could be explained in several ways. It seems likely that many of these patients will have had an anemia of chronic disease, which would be supported by the higher level of cancer deaths (8.8 % vs 2.4 % in those with angioectasia). It is also plausible that a significant number of those with a "normal" SBCE did in fact have iron deficiency or bleeding secondary to angioectasia either elsewhere within the gastrointestinal tract or missed within the small bowel. This could be suggested by a significant overlap in the comorbidities and clinical outcomes of the patients. It is possible some of these patients had pathology in their upper or lower gastrointestinal tract that had been missed on investigation. As such, the inclusion of those investigated for iron deficiency anemia or small bowel bleeding with a "normal" resultant CE is a poor control group and could not entirely be taken as such due to the degree of cohort bias. Ideally there would be an age matched healthy "control" group, but this is not available.

###### Summary of survival by subgroup.

  Group             Subgroup                                                             Number   \% 5-year survival (n = )
  ----------------- -------------------------------------------------------------------- -------- ---------------------------
  Angioectasia      No major comorbidities                                                22      81.1 % (18)
  Angioectasia      1--2 lesions                                                          41      70.7 % (29)
  No angioectasia   All                                                                  125      70.4 % (88)
  Angioectasia      3 of more lesions                                                     30      66.7 % (20)
  Angioectasia      All                                                                  125      64.0 % (80)
  No angioectasia   Cardiac/vascular comorbidity                                          63      63.5 % (40)
  Angioectasia      Requiring endoscopic treatment                                        37      62.2 % (23)
  Angioectasia      Chronic kidney disease                                                19      61.9 % (11)
  No angioectasia   Over 65 with at least 1 major comorbidity                             68      57.4 % (39)
  Angioectasia      Cardiac/vascular comorbidity without antiplatelets/ anticoagulants    32      53.1 % (17)
  Angioectasia      All with cardiac/vascular comorbidity                                 70      52.9 % (37)
  Angioectasia      Cardiac/vascular comorbidity with antiplatelets/ anticoagulants       37      51.4 % (19)
  Angioectasia      Over 65 with at least 1 major comorbidity                             66      45.5 % (19)

A reported 47 % of elderly people in nursing homes are anemic [@JR1739-10] , there is often only cursory investigation to exclude malignancy undertaken with symptomatic management following this. It is likely that a significant proportion of these patients will have angioectasia as the underlying pathology. Those undergoing SBCE are likely to represent a younger, healthier population, making the high mortality seen more striking and potentially over-estimating survival following a diagnosis of angioectasia. Despite this, those investigated in this study were older (median 72.7 years) and often multimorbid ( [Table 1](#TB1739-1){ref-type="table"} ).

Although none of the deaths were directly caused by bleeding from angioectasia, it is not unlikely that chronic anaemia may have contributed to cardiovascular disease, or affected management options. Those who required endoscopic therapy following a diagnosis of angioectasia of the SB had almost the same survival as those who did not (62.2 % vs 64.0 %). Those with one or two lesions were younger than those with three or more (70.0 vs 76.2 years) and had a marginally better 5-year survival rate (70.1 % vs 66.7 %).

These results suggest that the degree of angioectatic bleeding was not associated with increased mortality but merely their presence could be taken as a marker of comorbidity and frailty.

This study has certain limitations. The retrospective design relied on data collected from prior to June 2014, with many of these patients from other health boards having incomplete records available. The original reports for many, as seen in the results section, was lacking with variable documentation of the lesions and clinical course at the time of these procedures.

The small numbers available are due to the specificity of the cohort being examined, but this does make result difficult to interpret. This is particularly true for the subgroups, therefore, generalization of these findings would be less reliable.

Characterization of the initial patient presentation and degree of angioectatic bleeding proved to be difficult. The focus of this manuscript is on the frailty of those presenting with angioectasia and this proved to complicate the severity markers investigated. The initial presentations, hemoglobin levels and transfusion requirements, where recorded, were less reliable and difficult to interpret as they were affected by confounding patient factors.

Despite these limitations, this study represents real-world outcomes in frail and elderly patients who are commonly excluded from prospectively held research. We feel this is a major strength of this manuscript.

Five-year survival was poorest in those over 65 with at least one major comorbidity (45.5 %). This is comparable with those who have metastatic small bowel adenocarcinoma diagnosed (42 % 5 year survival) [@OR1739-7] .

Conclusion
==========

As hypothesized, those diagnosed with SB angioectasia are very frequently elderly and frail, and although the angioectasia did not cause any documented deaths, the 5-year survival was poor.
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